Noting the technological and regulatory advances that have been made since the North American Free Trade Agreement (NAFTA) took effect nearly 25 years ago, the U.S. biopharma and med-tech industries are pushing for a modernized NAFTA that will reflect the provisions in more recent trade agreements and at the same time raise the bar for future agreements.